XCUR Stock Forecast: Exicure, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Exicure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (20): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
XCUR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XCUR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 10 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Aug 2022 | Chardan Capital | Maintains | Neutral | $0.25 → $2.00 |
| 13 Dec 2021 | Chardan Capital | Downgrade | Neutral | $2.25 → $0.40 |
| 23 Nov 2021 | Chardan Capital | Maintains | Buy | $7.00 → $2.25 |
| 17 May 2021 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $6.00 |
| 18 Dec 2020 | BMO Capital | Initiates | Outperform | — |
| 17 Sept 2020 | Chardan Capital | Maintains | Buy | $5.00 → $7.00 |
| 20 Nov 2019 | Guggenheim | Initiates | Buy | — |
| 6 Nov 2019 | H.C. Wainwright | Initiates | Buy | — |
| 26 Mar 2019 | Chardan Capital | Initiates | Buy | — |
| 11 July 2018 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
XCUR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
XCUR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Exicure, Inc. returned −78.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
XCUR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 6.7×
- EV / EBITDA
- —
Cheaper than 12% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −168.4%
- Return on assets
- −30.3%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Exicure, Inc. has a market value of $6.4M and an enterprise value of $4.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.3M.
Free cash flow in the twelve months to 30 June 2026: −$6.4M.
Exicure, Inc. employs 1 people.
Data provided by Twelve Data
XCUR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at XCUR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Exicure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about XCUR
How does Ticker Nerd's model rank XCUR?
As at 21 Nov 2026, Exicure, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).
What is the XCUR stock forecast for 2030?
No analyst covering Exicure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XCUR are extrapolating price history, which says nothing about the business.
How has XCUR stock performed over the past year?
Exicure, Inc. returned -78.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Exicure, Inc. do?
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for blood-related diseases and other serious medical conditions. Its current focus includes small-molecule medicines designed to influence cellular signaling and mobilization, particularly through inhibition of the CXCR4 chemokine receptor.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for blood-related diseases and other serious medical conditions. Its current focus includes small-molecule medicines designed to influence cellular signaling and mobilization, particularly through inhibition of the CXCR4 chemokine receptor. The company’s lead clinical-stage asset, GPC-100, also known as burixafor, is being evaluated for its ability to mobilize hematopoietic stem cells and lymphocytes, supporting potential applications in hematology and oncology. Exicure, Inc. also maintains expertise in nucleic-acid-based drug development, including therapeutic platforms centered on spherical nucleic acids for immuno-oncology and genetic disorders. As a clinical-stage biotechnology business, the company’s role in the financial market is linked to the development and advancement of specialized pharmaceutical candidates rather than the commercial sale of a broad portfolio of approved medicines. Its activities place it within the biotechnology and pharmaceutical sectors, serving research, clinical-development, and healthcare markets.
CEO Mr. Jungsoo Kim · 1 employees · United States · https://www.exicuretx.com